Illumina (ILMN) Climbs 7.70% on May 13

Equities Staff  |

Illumina Inc (NASDAQ: ILMN) has gained $16.735 (7.70%) and is currently sitting at $232.32, as of 11:59:24 est on May 13.

652,536 shares exchanged hands.

The Company is down 25.47% over the last 5 days and shares fell 36.90% over the last 30 days.

Illumina is set to release earnings on 2022-08-04.

For technical charts, analysis, and more on Illumina visit the company profile.

About Illumina Inc

Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established it as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The Company products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

To get more information on Illumina Inc and to follow the company's latest updates, you can visit the company's profile page here: Illumina Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I
Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users
Squarespace Beats Revenue Estimates With Record Q1
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million
How To Trade in a Bearish Market
AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement



Market Movers

Sponsored Financial Content